Market research
SEEL Seelos Therapeutics Inc
OTCQB USD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 215K
- P/E ratio
- 0.0
- Analyst target
- 120
- Dividend yield
- Not available
- Beta
- 1.94
Profile
Instrument facts
- Exchange
- OTCQB
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 215K
- P/E ratio
- 0.0
- Analyst target
- 120
- Dividend yield
- Not available
- Beta
- 1.94
About
About Seelos Therapeutics Inc
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Research context
Seelos Therapeutics Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the SEEL discussion.
5 years, 6 months ago
Seelos Therapeutics, Inc is currently in a long term uptrend where the price is trading 5.0% above its 200 day moving average.
From a valuation standpoint, the stock is 57.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 572.5.
Seelos Therapeutics, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 37.3% to $-6M since the same quarter in the previous year.
Finally, its free cash flow grew by 35.0% to $-3M since the same quarter in the previous year.
Based on the above factors, Seelos Therapeutics, Inc gets an overall score of 4/5.